The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 11 3968-3972
Copyright © 2000 by The Endocrine Society
Megacolon as the Presenting Feature in Pheochromocytoma
Ann T. Sweeney,
Alan O. Malabanan,
Michael A. Blake,
Antonio de las Morenas,
Riad Cachecho and
James C. Melby
Departments of Medicine, Section of Endocrinology Diabetes and
Nutrition (A.T.S., A.O.M., J.C.M.), Radiology (M.A.B.), Pathology
(A.d.l.M.), and Surgery (R.C.), Boston University Medical Center,
Boston, Massachusetts 02118
Address all correspondence and requests for reprints to: Dr. James C. Melby, Endocrine Hypertension Unit, Department of Medicine and Physiology, Boston University School of Medicine, Evans Building, Room 232, Boston, Massachusetts 02118. E-mail:
James.Melby{at}bmc.org
 |
Introduction
|
|---|
Pheochromocytoma is a rare catecholamine-secreting tumor that may
present in a protean manner. Gastrointestinal manifestations of
pheochromocytoma are common and include nausea, vomiting, and abdominal
pain, but megacolon, in the absence of the multiple endocrine neoplasia
syndromes (MEN 2A and 2B), has rarely been described. In this
report megacolon was the presenting feature of the patients
pheochromocytoma. We discuss the role of catecholamines in the
pathogenesis of a megacolon and emphasize the importance of
recognizing this rare, but often lethal, combination.
 |
Case Report
|
|---|
A 38-yr-old female with a history of hypertension,
migraines, and constipation presented to our emergency room complaining
of severe abdominal pain and constipation. She had a 4-yr history of
constipation, with an average of two bowel movements per week. The pain
began 10 days before admission, was diffuse, and progressively
worsened. She had not had a bowel movement in 10 days. She described
increasing abdominal girth and nausea but no vomiting. Her medications
included hydrochlorothiazide (25 mg, orally, daily),
enalapril (10 mg, orally, daily), and over the counter laxatives as
needed. Her family history was noncontributory.
Physical examination revealed a thin female writhing in pain. Her blood
pressure was 182/155 mm Hg, heart rate was 116 beats/min, respirations
were shallow at 22/min, and temperature was 36.5 C. Her fundi were
without hemorrhages or exudates, and disk margins were sharp. Her
cardiac exam revealed a hyperdynamic precordium, normal first and
second heart sounds, and a II/VI systolic flow murmur at the left
sternal border. Examination was otherwise significant for a distended
abdomen with decreased bowel sounds and diffuse tenderness. Initial
laboratory studies revealed a white blood cell count of 19,000
mm-3 (SI; 19
x 109/L; normal range conventional; SI;
4:00011.,000 mm-3;
4.011 x 109/L) with a left shift,
hemoglobin of 14 g/dL (140 g/L; 13.518.0 g/dL; 135180 g/L),
platelet count of 276 x
103/mm3 (276 x
109/L; 150400 x
103/mm3; 150400 x
109/L), and normal electrolytes. Her abdominal
radiograph revealed large dilated loops of colon, a large amount of
stool in the cecum, and no gas within the rectum (Fig. 1
). The cecum was dilated to 10 cm. A
diagnosis of large bowel obstruction secondary to fecal impaction was
made. Attempt at manual disimpaction was unsuccessful.
After admission, the patient was treated with naso-gastric tube
decompression, pain control, and multiple enemas. Colonoscopy revealed
normal mucosa to 65 cm without any masses. Further examination was
impeded by impacted stool. Aggressive therapy with cathartics, external
enemas, and further nasogastric tube decompression was continued. A
gastrograffin enema revealed an obstructing fecal bolus within the
distal descending colon. She remained significantly hypertensive
throughout this period with systolic blood pressures ranging from
160220 mm Hg, and diastolic pressures ranging from 90120 mm Hg. She
was started on methyldopa, which was titrated to 750 mg, iv, every
6 h.
After 5 days in the hospital, her clinical situation worsened as she
developed increasing abdominal pain and distention. Abdominal plain
film demonstrated cecal dilatation to 13 cm. Urgent surgical
exploration revealed a megacolon with volvulus. A subtotal colectomy
with primary ileorectal anastamosis was performed. She was
significantly hypertensive during surgery and required multiple doses
of iv labetolol for blood pressure control. The patient did well
postoperatively until day 6, when she redeveloped acute abdominal pain
with peritoneal signs. A computed tomographic scan of the abdomen was
performed and revealed a small amount of fluid in the pelvis,
persistent pneumoperitoneum, and a 6 x 7-cm adrenal mass (Fig. 2
).

View larger version (107K):
[in this window]
[in a new window]
|
Figure 2. Axial abdominal computed tomographic scan
displays a well circumscribed mass (short arrow) of
heterogeneous soft tissue attenuation in the right suprarenal area.
Oral contrast is present in the stomach (long arrow).
|
|
Endocrine consultation revealed that her migraines and hypertension
began simultaneously 5 yr previously. She described experiencing severe
headaches accompanied by palpitations, skin warmth, and a sensation
that her blood pressure was rising. Initially these spells occurred
once a month, but had progressively increased to a few times per week.
The constipation also started around the same time and had become
progressively worse despite stool softeners and laxatives. Examination
was remarkable only for cachexia, tachycardia, and mild systolic
hypertension (140/79 mm Hg). She did not display marfanoid features or
have mucosal neuromas. An abdominal magnetic resonance imaging scan
demonstrated a 7 x 7-cm heterogeneous mass in the right adrenal
gland that appeared hyperintense on T2 weighted images consistent with
a pheochromocytoma. Therapy with phenoxybenzamine (10 mg, orally, twice
daily) dramatically lowered the patients blood pressure to 90/60 mm
Hg. Despite volume repletion, she remained significantly tachycardic,
with a heart rate of 120 beats/min or more. Atenolol (25 mg/day,
orally) was added and reduced her heart rate to approximately 90
beats/min.
Her 24-h urine results confirmed the diagnosis of pheochromocytoma. The
24-h urine collection revealed: norepinephrine, 883 µg (5,219 nmol;
normal, 1186 µg/day; 65508 nmol/day); epinephrine, 675 µg
(3,685 nmol; 015 µg/day; 081.9 nmol/day); dopamine, 441 µg
(2,879 pmol; 100400 µg/day; 6532,612 pmol/day); total
unconjugated catecholamines, 1,999 µg (11,816 nmol; <540 µg/day;
<3,191 nmol/day); and total metanephrines, 17.1 mg (93.33 µmol;
<1.3 mg/day; <7.13 µmol/day). Other laboratory results included
serum calcitonin, 2 pg/mL (0.58 pmol/L; <5 pg/mL; <1.45 pmol/L);
intact PTH, 34 pg/mL (34 ng/L; 1065 pg/mL; 1065. ng/L); and
calcium, 10.0 mg/dL (2.50 mmol/L; 8.410.2 mg/dL; 2.12.55
mmol/L).
After adequate
and ß blockade, she underwent surgical resection
of her right adrenal gland. Intraoperatively her blood pressure was
labile during manipulation of the tumor, and she required large doses
of iv nitroprusside and esmolol. A 200-g, well circumscribed mass was
removed without complications. Postoperatively she was transiently
hypotensive and required a large amount of fluid as well as temporary
support with vasopressors.
Pathology
Gross examination revealed a 200-g, 4 x 7 x 8-cm
encapsulated pheochromocytoma. The cut surface was reddish brown with
yellow areas of necrosis. Microscopically, the tumor cells were
arranged in circular clusters separated by endothelium lined spaces;
this characteristic pattern for pheochromocytoma is termed zellballen
(Fig. 3
).

View larger version (136K):
[in this window]
[in a new window]
|
Figure 3. Microscopic view (hematoxylin-eosin stain;
magnification, x100) of pheochromocytoma showing typical
zellballen pattern with nests of cells separated by thin
vascular stroma.
|
|
Histological examination of the colectomy specimen revealed focal
mucosal coagulation necrosis, submucosal hemorrhage, and acute and
chronic inflammatory infiltrate. No abnormality was noted in the
myenteric plexus, and there was no evidence of ganglioneuromatosis.
Follow-up
She was last seen 10 months after surgery; she remains
normotensive without medication and has experienced no further spells.
Her constipation has completely resolved. Repeat 24-h urine for total
catecholamines, metanephrines, and vanillylmandelic acid returned
within normal limits. The serum chromogranin A level was within the
normal range, and screening for mutations in the RET protooncogene was
negative. No mutations were detected in exons 10 (codons 609, 611, 618,
and 620), 11 (codon 634), 13, 14, or 16 (codon 918) of the RET
protooncogene.
 |
Discussion
|
|---|
Pheochromocytoma classically presents with hypertension in
association with palpitations, headaches, and diaphoresis. This
constellation of symptoms is said to be 91% sensitive and 94%
specific for the diagnosis of pheochromocytoma (1). Our
patient displayed all of these symptoms; however, her initial
presentation with an ileus and megacolon may not immediately bring to
mind the diagnosis of pheochromocytoma. The differential diagnosis for
megacolon includes Hirschprungs, Chagas, and Parkinsons diseases;
diabetic neuropathy; myotonic dystrophy; hypothyroidism; amyloidosis;
and pheochromocytoma. A few standard internal medicine textbooks do not
even list pheochromocytoma in the differential diagnosis of megacolon
(2, 3).
The typical gastrointestinal manifestations of pheochromocytoma include
nausea, vomiting, and abdominal pain. Constipation has been reported in
513% of cases in a larger series (4). Megacolon and
pheochromocytoma may occur together in MEN 2A and MEN 2B.
Hirschprungs disease, or congenital aganglionic colon, has been
reported in association with both MEN 2A and 2B syndromes
(5). In MEN 2A, at least six germline mutations (involving
codons 609, 611, 618, and 620) of the RET protooncogene located on
chromosome 10 (10q11.2) have been identified (6). Evidence
has demonstrated that Hirschsprungs disease is also linked to the RET
protooncogene (7). Patients with MEN 2B and
neurofibromatosis may also develop megacolon (8). Diffuse
ganglioneuromatosis of the colon in MEN 2B is thought to cause a
dysmotility syndrome that may precipitate megacolon (9). A
germline missense mutation in the tyrosine kinase domain of the RET
protooncogene (exon 16, codon 918) has been reported to be present in
95% of patients with MEN 2B (10). Our patients
phenotypic features, colon pathology, and genetic testing clearly were
not consistent with Hirschprungs disease, MEN 2A, or MEN 2B.
Sustained high catecholamine levels secreted by a high tumor burden may
explain the mechanism by which constipation, paralytic ileus, and
megacolon occur in association with pheochromocytoma. The effects of
catecholamines on intestinal smooth muscle and the splanchnic
circulation are well known (11). Stimulation of
receptors causes hyperpolarization and relaxation of intestinal smooth
muscle (
1), constriction of intestinal
vascular smooth muscle (
1 and
2), and contraction of ileocolic sphincters
(
2). Stimulation of ß2
receptors causes arteriolar dilatation and intestinal smooth muscle
relaxation. Therefore, high levels of circulating catecholamines will
result in a decrease in intestinal peristalsis, motility, and tone.
Clinically this may manifest initially as intermittent constipation,
but when catecholamine levels become persistently elevated, they may
precipitate an ileus or perhaps a megacolon. Cruz and Colwell reported
a series of seven patients who developed ileus with large
pheochromocytomas (>70 g) and catecholamine levels at least twice
normal (>1,000 µg/day; 5,910 nmol/day) (12). As shown
in Table 1
, only the largest
pheochromocytomas (>200 g) with circulating catecholamine levels
approaching 4 times normal (>1,999 µg/day; 11,814 nmol/day)
developed megacolon.
View this table:
[in this window]
[in a new window]
|
Table 1. Review of the literature: cases of megacolon,
paralytic ileus, or pseudoobstruction in association with
pheochromocytoma
|
|
Factors other than serum catecholamines may play a role in the
development of ileus or megacolon. There is evidence that opioid
peptides may be synthesized and secreted by pheochromocytomas
(13). As narcotic analgesics are known to induce
constipation and megacolon, perhaps a noncatecholamine product, such as
an opioid compound, may have played a contributory role in the
pathogenesis of megacolon.
Some patients with pheochromocytoma and pseudo-obstruction,
however, have been reported to have a dramatic relief after the iv
administration of phentolamine, an
-adrenergic blocker. This
suggests that
-adrenergic activation by high circulating
catecholamine levels is largely responsible for pseudo-obstruction
observed in patients with pheochromocytoma (14, 15).
The effects of catecholamines on the intestine were initially described
by Blacket et al. in 1950 (16). They
continuously infused noradrenaline to four rabbits over 4 days. This
resulted in the premature death of one rabbit that at autopsy was found
to have enormous dilatation of the large gut. Two of the other rabbits
subsequently became ill and on postmortem exam also exhibited gross
dilatation of the terminal large gut.
Review of the literature reveals that the presence of megacolon in
association with pheochromocytoma carries a grave prognosis (see Table 1
). Our patient was extremely fortunate to have survived a total
colectomy before the discovery of her pheochromocytoma. Perhaps the
diagnosis could have been made sooner had the association of megacolon
and pheochromocytoma been recognized.
Conclusion
In summary, we describe a patient with a history of hypertension,
migraine headaches, and constipation presenting with severe abdominal
pain and megacolon who ultimately was found to have a pheochromocytoma.
High circulating catecholamine levels secreted by the large tumor
undoubtedly precipitated the megacolon. We conclude that the diagnosis
of pheochromocytoma should be considered in any patient who presents
with megacolon, pseudo-obstruction, and features of catecholamine
excess.
Received January 20, 2000.
Revised July 10, 2000.
Accepted July 18, 2000.
 |
References
|
|---|
-
Poulin PF, Degoulet P, Tugaye A, Ducrocq MB, Menard
J. 1981 Screening for pheochromocytoma: in which hypertensive
patients? A semiological study of 2585 patients, including 11 with
pheochromocytoma. Nouv Presse Med. 10:869872.[Medline]
-
Kelly W, ed. 1997 Textbook of internal
medicine. Philadelphia: Lippincott-Raven.
-
Goldman E, Bennet J, eds. 2000 Cecil textbook of
medicine, 2nd Ed. Philadelphia: Saunders.
-
Gifford RW, Kvale WF, Maher FT, Roth GM, Priestley
JT. 1964 Clinical features, diagnosis and treatment of
pheochromocytoma: a review of 76 cases. Mayo Clin Proc. 39:281302.[Medline]
-
Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu
P. 1982 Hirshprungs disease in a family with multiple endocrine
neoplasia type II. J Pediatr Gastroenterol Nutr. 1:603607.[Medline]
-
Eng C, Clayton D, Schuffenecker I, et al. 1996 The
relationship between specific RET proto-oncogene mutations and disease
phenotype in multiple endocrine neoplasia type 2: international RET
mutation analysis. JAMA. 276:15751579.[Abstract]
-
Edery P, Lyonnet S, Mulligan LM, et al. 1994 Mutations of the RET proto-oncogene in Hirshprungs disease. Nature. 367:378380.[CrossRef][Medline]
-
Whittle JS, Goodwin MN. 1976 Intestinal
ganglioneuromatosis with the mucosal neuroma-medullary thyroid
carcinoma-pheochromocytoma syndrome. Am J Gastroenterol. 65:248257.
-
ORiordan DS, OBrien T, Crotty TB, Gharib H, Grant
CS, van Heerden JA. 1995 Multiple endocrine neoplasia type 2B:
more than an endocrine disorder. Surgery. 118:936942.[CrossRef][Medline]
-
Gordon CM, Majzoub JA, Marsh DJ et al. 1998 Four
cases of mucosal neuroma syndrome: multiple endocrine neoplasm 2B or
nor 2B? J Clin Endocrinol Metab. 83:1720.[Free Full Text]
-
Goodman L, Gilman A. 1985 The pharmacologic
basis of therapeutics. New York: MacMillan; 148.
-
Cruz SR, Colwell JA. 1972 Pheochromocytoma and
ileus. JAMA. 219:10501051.[CrossRef][Medline]
-
Wilson SP, Cubeddu LX, Chang KJ, Viveros OH. 1981 Met-enkephalin, leu-enkephalin and other opiate-like peptides in human
pheochromocytoma tumors. Neuropeptides. 1:273281.
-
Bernstein A, Spencer D, Wright AC. 1967 Pheochromocytoma as a cause of gastrointestinal distention. Postgrad
Med. 43:180183.[Medline]
-
Khafagi FA, Gough IR, Lloyd HM. 1987 Intestinal
pseudo-obstruction in pheochromocytoma. Aust NZ J Med. 17:246248.[Medline]
-
Blacket RB, Pickering GW, Wilson GM. 1950 The
effects of prolonged infusion of noradrenaline and adrenaline on the
arterial pressure of the rabbit. Clin Sci. 9:247251.
-
Duffy TJ, Erickson EE, Jordan GL, Bennett, HD. 1962 Megacolon and bilateral pheochromocytoma. Am J Gastroenterol. 38:555563.
-
Suba AR. 1971 Bilateral pheochromocytoma with
megacolon. Mol Med. 68:256258.
-
Francis RS. 1976 X-Ray of the month. J Tenn
Med Assoc. 69:114142.[Medline]
-
Rosati LA, Augur NA. 1971 Ischemic enterocolitis in
pheochromocytoma. Gastroenterology. 60:581585.[Medline]
-
Mullen JP, Cartwright RC, Tisherman SE, Misage JR,
Shapiro AP. 1985 Case report: pathogenesis and pharmacologic
management of pseudo-obstruction of the bowel in pheochromocytoma. Am J Med Sci. 290:155158.[Medline]
-
Turner CE. 1983 Gastrointestinal pseudo-obstruction
due to pheochromocytoma. Am J Gastroenterol. 78:214217.[Medline]
-
Hughes LE, Bolt DE, Hobson QJG. 1962 Pheochromocytoma: presenting as resistant intestinal ileus. Proc R Soc
Med. 55:998999.
-
Huston JR, Stewart WR. 1965 Hemorrhagic
pheochromocytoma with shock and abdominal pain. Am J Med. 39:502504.[CrossRef][Medline]
-
Fred HL, Allred DP, Garber HE, Retiene K, Lipscomb
H. 1967 Pheochromocytoma masquerading as overwhelming infection. Am Heart J. 73:149154.[Medline]
-
Brown RB, Borowsky M. 1960 Further observations on
intestinal lesions associated with pheochromocytomas. A case of
malignant pheochromocytoma in pregnancy. Ann Surg. 151:683692.[Medline]
-
Zacher LL, Teslow TW, Thompson RF. 1989 Pheochromocytoma and ischemic enterocolitis. S D J Med. 42:1114.
-
Bernstein A, Spencer D, Wright AC. 1967 Pheochromocytoma as a cause of gastrointestinal distention. Postgrad
Med. 43:180183.
-
Cole L. 1950 The early diagnosis of
pheochromocytoma. Br Heart J. 12:232238.